QIAGEN NV

NYSE: QGEN (Qiagen N.V.)

Last update: 5 days ago, 8:11AM

49.89

-0.21 (-0.42%)

Previous Close 50.10
Volume 1,642,136
Price / Earnings (Forward) 15.45
Price / Sales 4.91
Price / Book 2.96
52 Weeks Range
32.53 (-34%) — 57.82 (15%)
TTM Dividend Yield 0.64%
Profit Margin 4.68%
Operating Margin (TTM) 25.89%
Diluted EPS (TTM) 0.430
Quarterly Revenue Growth (YOY) 5.40%
Quarterly Earnings Growth (YOY) 12.50%
Total Debt/Equity (MRQ) 41.36%
Current Ratio (MRQ) 3.37
Operating Cash Flow (TTM) 680.21 M
Levered Free Cash Flow (TTM) 622.84 M
Return on Assets (TTM) 5.75%
Return on Equity (TTM) 2.67%

AIStockmoo Score

2.3
Around its usual valuation. Counted for less, as its earnings have been uneven. info
Earns below its cost of capital. info
Low debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
No clear trend over the past year. Trading near its 52-week high. info
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. Volume is heavier on up days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Institutions net +6.34% of shares in their latest 13F filings: 218 holders increased, 153 decreased (quarter to 30 Sep 2026). info
Insider Activity info NA
Market environment cautious. info
Sector outperforming the market.
The pillars agree, so the score is strengthened.
Earnings per share have gone up and down. Earnings have been uneven. info
Above its medium-term trend line. info
Price is high against its 52-week average. Down over 5 years. info
Trend up on all three terms. Short-term momentum fading. info
Price is near resistance. Levels trending up. info
Final Score 2.27
Show all

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Mixed Bullish
Diagnostics & Research (Global) Mixed Bullish
Stock Qiagen N.V. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
QGEN - 0.64% - 2.96 2.3
RVTY 17 B 0.18% 67.67 2.34 0.9
CRL 16 B - 356.45 4.94 0.7
TMO 248 B 0.27% 35.31 4.69 0.7
DHR 155 B 0.67% 36.48 3.00 0.4
WAT 87 B - 184.29 5.99 1.2

Select this tab to load the latest available analysis.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Sector Healthcare
Industry Diagnostics & Research
Investment Style Small Core
% Held by Insiders 1.61%
% Held by Institutions 86.26%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 76.28%

Positions Holders Shares
Increased 218 31,874,519
Decreased 153 18,912,886
New 67 5,570,055
Sold out 52 5,474,496

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

0 Positive 1 Negative 3 Neutral
Date Type Details
13 Nov 2026 Yahoo Finance Interpreting Qiagen (QGEN) International Revenue Trends
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
11 Nov 2026 Yahoo Finance Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director
Qiagen (NYSE:QGEN) received shareholder approval at an Extraordinary General Meeting for Jonathan M. Pratt to become CEO and Managing Director. Jonathan M. Pratt is set to succeed Thierry Bernard in the top leadership role following the Extraordinary General Meeting vote. The board decision…
06 Nov 2026 Yahoo Finance Qiagen (QGEN) Stock May Be Fully Priced As Sequencing Project Expands
Qiagen has delivered a 35.3% gain over the past three years, and recent headlines around genomics partnerships and sequencing markets keep the story in focus. The question now is whether that share price trajectory lines up with what the company’s cash flows can reasonably support. With a 35.3%…
06 Nov 2026 Yahoo Finance QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director
VENLO, Netherlands, November 06, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of…

Technical Setup Medium

Trend order
Slope
Entry
Volume
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. Volume is heavier on up days.
Nearest support: 47.11 – 47.45 · moderate level
Nearest resistance: 49.90 – 50.24 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria